News Image

MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function

Provided By GlobeNewswire

Last update: Jan 18, 2025

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function.

Read more at globenewswire.com

INNOVATE CORP

NYSE:VATE (7/25/2025, 8:04:00 PM)

5.81

+0.11 (+1.93%)



Find more stocks in the Stock Screener

Follow ChartMill for more